EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
独家：减肥市场专家在药物试验失利后，因自2002年以来最大跌幅而纷纷购买诺和诺德股票
Novo Nordisk A/S (NYSE:NVO) saw its stock crater nearly 20% on Friday, eyeing its worst single-day drop since April 2002, after releasing underwhelming weight-loss trial results for its much-hyped obesity drug, CagriSema.
诺和诺德A/S（纽交所：NVO）在周五股价暴跌近20%，创下自2002年4月以来最大的单日跌幅，此次暴跌是由于其备受关注的肥胖药物CagriSema发布了令人失望的减肥试验结果。
To put the move in perspective, the only steeper plunge in the Danish pharma giant's history was a 26.2% collapse during the infamous Black Monday crash of October 1987.
为了让这一波动有个参考，丹麦制药巨头历史上唯一更大幅度的下跌是在1987年10月著名的黑色星期一崩盘期间，其股价下跌了26.2%。
Once the poster child of the obesity drug boom, Novo failed to meet the market's sky-high expectations, sparking a $20 billion wipe out in market value.
曾经是肥胖药物热潮的代表，诺和诺德未能满足市场高涨的预期，导致市值蒸发达200亿。
Here's what happened—and why some analysts believe Wall...
这就是发生了什么——...
登录免费看全文
登录/注册
资讯热榜
更新时间